10-Q: AirSculpt Technologies Q2 2026: Revenue Dips Amidst Rising Costs

AirSculpt Technologies reported a decrease in revenue and an increase in operating expenses for the second quarter of 2026, leading to a net loss, while also addressing material weaknesses in internal controls.

Summary

• AirSculpt Technologies reported a net loss of $1.112 million for the three months ended June 30, 2026, compared to a net loss of $591,000 for the same period in 2025. For the six months ended June 30, 2026, the net loss was $3.509 million, compared to $3.438 million in the prior year.
• Revenue for the second quarter of 2026 was $42.9 million, a decrease of 2.5% from $44.0 million in the second quarter of 2025. For the first six months of 2026, revenue was $82.3 million, a decrease of 1.3% from $83.4 million in the first six months of 2025.
• Cost of services decreased by 3.7% for the quarter and 3.0% for the six months, attributed to efficiencies in personnel costs and medical supplies.
• Selling, general, and administrative (SG&A) expenses increased by 3.3% for the quarter and 3.5% for the six months, primarily driven by higher advertising expenses.
• The company continues to experience material weaknesses in its internal control over financial reporting, particularly in general accounting processes and lease accounting.
• The company has amended its credit agreement, extending the maturity date and introducing new payment requirements and equity proceeds application rules.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to declining revenues, increased operating expenses, and continued net losses, despite some operational efficiencies. The company is also facing challenges with internal controls.

Positives

• Cost of services decreased by 3.7% for the quarter and 3.0% for the six months, indicating improved operational efficiencies.
• Same-center case volume increased by 1.0% for the quarter and 1.1% for the six months, suggesting stable core business performance.
• The company has $18.8 million in cash and cash equivalents as of June 30, 2026, providing a buffer for operations.
• The company has $5.0 million available on its revolving credit facility.

Negatives

• Revenue declined by 2.5% for the quarter and 1.3% for the six months, indicating a challenging market or execution.
• Net loss widened for the quarter to $1.112 million and increased for the six months to $3.509 million.
• Selling, general, and administrative expenses increased by 3.3% for the quarter and 3.5% for the six months, largely due to increased advertising spend.
• The company reported material weaknesses in internal control over financial reporting, which have not yet been fully remediated.
• The company's debt agreement was amended, requiring significant upcoming payments and dedicating 50% of future equity proceeds to debt repayment.

Risks

• The company faces risks related to the inability to stabilize and grow same-center performance.
• There is a risk of not being able to optimize marketing investment, go-to-market strategy, and sales processes.
• The company may face challenges in expanding financing options for consumers.
• Increased competition in the weight loss and obesity solutions market, including from weight-loss drugs, poses a risk.
• Shortages or quality control issues with third-party manufacturers or suppliers could impact operations.
• Competition for surgeons and potential litigation or medical malpractice claims are ongoing risks.
• Changes in laws governing the corporate practice of medicine or fee-splitting could affect the business.
• Macroeconomic conditions, including inflation and the threat of recession, could negatively impact the business.

Future Outlook

The company believes that cash expected to be generated from operations will be sufficient for its working capital requirements, liquidity obligations, and payments due under existing credit facilities for at least the next 12 months. However, the company's ability to improve operating results depends on numerous factors, some beyond its control, and failure to implement growth strategies successfully could adversely affect operating results and liquidity.

Management Comments

• We provide custom body contouring using our proprietary AirSculpt method that removes unwanted fat and tightens skin in a minimally invasive procedure, producing dramatic results.
• Our revenue decreased $1.1 million, or 2.5%, compared to the same period in 2025. This decline was driven primarily by a 2.0% decrease in average selling price on a same-center basis, partially offset by a 1.0% increase in same-center case volume.
• Selling, general and administrative expenses increased $0.8 million, or 3.3%, for the three months ended June 30, 2026 compared to the same period in 2025. This increase is driven primarily by a $1.4 million increase in advertising expense.

Industry Context

StockSavvy.ai notes that AirSculpt operates in the competitive body contouring and weight loss market, which is increasingly influenced by the availability and acceptance of weight-loss drugs. The company's revenue decline and increased marketing spend suggest pressure from competition and potentially shifting consumer preferences.

Comparison to Industry Standards

• The filing does not provide specific comparisons to industry benchmarks or competitors.
• The company's revenue per case of approximately $12,707 for Q2 2026 is a key internal metric but lacks external comparative data within this filing.

Legal Proceedings

• The company is involved in pending and threatened legal actions and proceedings, primarily related to medical malpractice claims concerning services provided by employed and affiliated physicians.
• The company believes the outcome of current legal actions will not materially adversely affect its financial condition, results of operations, or cash flows, but acknowledges that an unfavorable resolution could have such an effect.
• Insurance coverage is maintained, but there is no assurance it will be adequate for all future claims.

Stakeholder Impact

• Shareholders may be impacted by the continued net losses, declining revenue, and the increased focus on debt repayment, which could limit future growth or equity value.
• Creditors are impacted by the amendment to the credit agreement, which imposes stricter terms and requires significant debt repayment from future equity issuances.
• Employees may be affected by the company's financial performance and ongoing efforts to address internal control weaknesses.

Next Steps

• Continue remediation efforts for material weaknesses in internal control over financial reporting, including enhancing lease accounting controls and engaging external advisors.
• Evaluate the accounting treatment (modification or extinguishment) for the Fourth Amendment to the Credit Agreement.
• Make a $2.5 million payment on the term loan by September 30, 2026, as required by the Fourth Amendment.
• Provide biweekly updates to lenders on efforts to discharge obligations under the credit agreement.
• Retain investment banks by October 31, 2026, if Discharge of Obligations has not occurred, to secure replacement debt financing or otherwise.

Key Dates

Recommendation

The company shows signs of operational strain with declining revenue and widening losses, coupled with persistent internal control weaknesses. While there are some operational efficiencies and a cash buffer, the increased debt servicing obligations and competitive pressures warrant a cautious approach. A 'hold' recommendation reflects the uncertainty and the need for the company to demonstrate a clear path to profitability and improved financial controls.

Keywords

body contouring, liposuction, medical procedures, revenue decline, operating expenses, net loss, credit agreement amendment, internal controls